297. アラジール症候群 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 45 / 薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
3 MG [14C]-A4250 capsule
   Albireo
      2017   Phase 1   NCT03082937   United Kingdom
A4250
   ALBIREO AB
      2021   Phase 3   EUCTR2020-004011-28-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
   Albireo
      2013   Phase 1   NCT02963077   -
   Albireo AB
      2022   Phase 3   EUCTR2021-000996-36-NL   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000996-36-BE   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2021-000996-36-PL   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2021-000996-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2020-004011-28-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      -   Phase 3   EUCTR2020-004011-28-BE   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
A4250-015
   ALBIREO AB
      2021   Phase 3   EUCTR2021-000996-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
Atorvastatin
   Children's Hospital of Fudan University
      2022   Phase 4   NCT05488067   China
Eicosapentaenoic acid
   Sumida Wataru
      2016   -   JPRN-jRCTs041180088   -
LUM001
   Lumena Pharmaceuticals Inc
      2014   Phase 2   EUCTR2013-005373-43-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom
      -   Phase 2   EUCTR2013-005373-43-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom
   Lumena Pharmaceuticals LLC
      2015   Phase 2   EUCTR2013-005373-43-BE   Australia;Belgium;France;Poland;Spain;United Kingdom
   Lumena Pharmaceuticals, Inc.
      2013   -   EUCTR2012-005346-38-GB   United Kingdom
   Mirum Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004628-40-FR   Belgium;France;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-004628-40-BE   Belgium;Brazil;France;Mexico;Poland;United Kingdom;United States
      -   Phase 2   EUCTR2020-004628-40-PL   Belgium;Brazil;France;Mexico;Poland;United Kingdom;United States
   Mirum Pharmaceuticals Inc.
      2020   Phase 2   EUCTR2019-002755-42-GB   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002755-42-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002755-42-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2019-002755-42-PL   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   NCT02117713   Canada;United States
      2015   Phase 2   EUCTR2013-005373-43-GB   Australia;Belgium;France;Poland;Spain;United Kingdom
      2014   Phase 2   NCT02160782   Australia;Belgium;Canada;France;Germany;Poland;Spain;United Kingdom
      2014   Phase 2   NCT02057692   Canada;United States
      2013   Phase 2   NCT02047318   United Kingdom
      2013   Phase 2   NCT01903460   United Kingdom
      2013   Phase 2   EUCTR2013-003832-54-GB   United Kingdom
   Mirum Pharmaceuticals,Inc.
      -   Phase 2   EUCTR2013-005373-43-PL   Australia;Belgium;France;Poland;Spain;United Kingdom
   Shire Human Genetic Therapies Inc
      2015   Phase 2   EUCTR2015-000906-20-GB   Australia;Canada;United Kingdom;United States
Magnesium gluconate
   National Center for Research Resources (NCRR)
      2000   -   NCT00007033   United States
Magnesium sulfate
   National Center for Research Resources (NCRR)
      2000   -   NCT00007033   United States
Maralixibat
   Mirum Pharmaceuticals, Inc.
      2023   -   NCT06193928   United States
      2021   Phase 2   NCT04729751   Belgium;Brazil;France;Mexico;Poland;United Kingdom;United States
      2020   -   NCT04530994   United States
      2015   Phase 2   NCT02117713   Canada;United States
      2013   Phase 2   NCT02047318   United Kingdom
Maralixibat (formely SHP625 or LUM001)
   Mirum Pharmaceuticals Inc.
      2020   Phase 2   EUCTR2019-002755-42-BE   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
Maralixibat chloride
   Mirum Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-004628-40-FR   Belgium;France;Poland;United Kingdom
      2021   Phase 2   EUCTR2020-004628-40-BE   Belgium;Brazil;France;Mexico;Poland;United Kingdom;United States
      -   Phase 2   EUCTR2020-004628-40-PL   Belgium;Brazil;France;Mexico;Poland;United Kingdom;United States
   Mirum Pharmaceuticals Inc.
      2020   Phase 2   EUCTR2019-002755-42-GB   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002755-42-FR   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-002755-42-ES   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2019-002755-42-PL   Australia;Belgium;Canada;France;Poland;Spain;United Kingdom;United States
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   EUCTR2013-005373-43-GB   Australia;Belgium;France;Poland;Spain;United Kingdom
      2013   Phase 2   EUCTR2013-003832-54-GB   United Kingdom
   Mirum Pharmaceuticals,Inc.
      -   Phase 2   EUCTR2013-005373-43-PL   Australia;Belgium;France;Poland;Spain;United Kingdom
Odevixibat
   ALBIREO AB
      2021   Phase 3   EUCTR2021-000996-36-IT   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
   Albireo
      2021   Phase 3   NCT04674761   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
   Albireo AB
      2022   Phase 3   EUCTR2021-000996-36-NL   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000996-36-BE   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-NL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004011-28-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2021-000996-36-PL   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Türkiye;United Kingdom;United States
      -   Phase 3   EUCTR2021-000996-36-DE   Belgium;Canada;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2020-004011-28-PL   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;United Kingdom;United States
      -   Phase 3   EUCTR2020-004011-28-BE   Australia;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Malaysia;Netherlands;New Zealand;Poland;Turkey;United Kingdom;United States
   Albireo, an Ipsen Company
      2021   Phase 3   NCT05035030   Belgium;France;Germany;Italy;Malaysia;Netherlands;Poland;Turkey;United Kingdom;United States
Phenylbutyrate
   Juntendo University
      2014   -   JPRN-UMIN000012782   Japan
   Saiseikai Yokohama City Tobu Hospital
      2010   -   JPRN-UMIN000003802   Japan
Questran
   Albireo
      2013   Phase 1   NCT02963077   -
TAK-625
   Takeda
      2023   Phase 3   NCT05543174   Japan